Salk Institute Board of Trustees elects two visionary business leaders

December 9, 2013

Salk Institute Board of Trustees elects two visionary business leaders

December 9, 2013

LA JOLLA, CA—The Salk Institute is pleased to announce that Alan D. Gold and David F. Hale have been elected to its Board of Trustees.

“Alan and David each bring outstanding records of entrepreneurial success and business expertise to Salk,” said Irwin M. Jacobs, Chairman of the Salk Institute Board of Trustees. “We are greatly pleased to have them join our Board of Trustees.”

Alan D. Gold is chairman and chief executive officer of Biomed Realty, a publicly traded REIT specializing in acquiring and managing laboratory properties for lease to the life science industry. Mr. Gold also served as president of BioMed’s privately held predecessor, Bernardo Property Advisors, Inc. He was a co-founder and served as president and as a director of Alexandria Real Estate Equities, Inc. He was managing partner of GoldStone Real Estate Finance and Investments, a partnership engaged in the real estate and mortgage business. He also served as assistant vice president of Commercial Real Estate for Northland Financial Company, a full service commercial property mortgage banker, and as Real Estate Investment Officer – Commercial Real Estate for John Burnham Company, a regional full service real estate company. He currently serves on the Campanile Foundation Board supporting San Diego State University.

David F. Hale is chairman and chief executive officer of Hale BioPharma Ventures, LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic, and medical device companies. He also serves as executive chairman of Biocept, Inc., a cancer diagnostic company working on the detection and analysis of circulating tumor cells. Previously, he was president and chief executive officer of CancerVax Corporation from October 2000 through its merger in May 2006 with Micromet, Inc. where he served as chairman until its acquisition by Amgen Inc. in 2012. Additionally, Mr. Hale is chairman of Santarus, Inc., and a founding director and chairman of Conatus Pharmaceuticals, Inc. He is a co-founder and chairman of numerous other companies. Mr. Hale currently serves on the board of directors of BIOCOM, which he co- founded, and the San Diego Economic Development Corporation. He is a former member of the board of the Biotechnology Industry Organization (BIO) and the Biotechnology Institute. He is a co-founder and a director of CONNECT, acts as chairman of the board of trustees of Rady Children’s Hospital, and is a member of Rady School of Management Dean’s Advisory Council.

关于索尔克生物研究所：
索尔克生物研究所是世界顶尖的基础研究机构之一，其国际知名的教职人员在一个独特、协作和富有创造性的环境中，深入探究生命科学的基本问题。索尔克科学家们致力于发现和指导未来几代研究人员，通过研究神经科学、遗传学、细胞和植物生物学以及相关学科，在癌症、衰老、阿尔茨海默氏症、糖尿病和传染病的认识方面做出了开创性的贡献。.

学院取得了许多成就，获得了包括诺贝尔奖和美国国家科学院院士在内的无数荣誉。该研究所由脊髓灰质炎疫苗先驱 Jonas Salk 博士于 1960 年创立，是一家独立的非营利组织和建筑地标。.